Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T. Foley JF, et al. Among authors: lasky t. Neurol Neuroimmunol Neuroinflamm. 2024 Dec;11(6):e200321. doi: 10.1212/NXI.0000000000200321. Epub 2024 Oct 11. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39393045 Free PMC article. Clinical Trial.
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Ryerson LZ, et al. Among authors: lasky t. Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. Mult Scler Relat Disord. 2023. PMID: 36931078 Free article. Clinical Trial.
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2).
Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Domingo-Horne R, Toukam M, Nunn A, Maghzi AH, Kuhelj R, Lasky T. Wiendl H, et al. Among authors: lasky t. Neurol Ther. 2024 Oct;13(5):1385-1401. doi: 10.1007/s40120-024-00647-0. Epub 2024 Jul 24. Neurol Ther. 2024. PMID: 39046635 Free PMC article.
Resilience in rural health system.
Lasky T, Samanta D, Sebastian W, Calderwood L. Lasky T, et al. Clin Teach. 2024 Aug;21(4):e13726. doi: 10.1111/tct.13726. Epub 2024 Jan 28. Clin Teach. 2024. PMID: 38282472
A Descriptive Cohort Study of Drug Utilization Patterns Among Patients Hospitalized With Coronavirus Disease 2019 in the United States, January 2021-February 2022.
Vititoe SE, Govil P, Baglivo A, Beebe E, Garry EM, Gatto NM, Lasky T, Chakravarty A, Bradley MC, Perez-Vilar S, Rivera DR, Quinto K, Clerman A, Rajpal A, Frajzyngier V. Vititoe SE, et al. Among authors: lasky t. Open Forum Infect Dis. 2023 Jul 10;10(7):ofad339. doi: 10.1093/ofid/ofad339. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37496608 Free PMC article.
Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States.
Rodriguez-Watson CV, Sheils NE, Louder AM, Eldridge EH, Lin ND, Pollock BD, Gatz JL, Grannis SJ, Vashisht R, Ghauri K, Valo G, Chakravarty AG, Lasky T, Jung M, Lovell SL, Major JM, Kabelac C, Knepper C, Leonard S, Embi PJ, Jenkinson WG, Klesh R, Garner OB, Patel A, Dahm L, Barin A, Cooper DM, Andriola T, Byington CL, Crews BO, Butte AJ, Allen J. Rodriguez-Watson CV, et al. Among authors: lasky t. PLoS One. 2023 Feb 10;18(2):e0281365. doi: 10.1371/journal.pone.0281365. eCollection 2023. PLoS One. 2023. PMID: 36763574 Free PMC article.
53 results